Doctors Revision

Anticonvulsants: Seizure-Specific Pharmacology, Dosing and Safety

Text size
On this page

1 Overview

Anticonvulsants (antiepileptic drugs, AEDs) suppress abnormal neuronal firing without abolishing normal transmission. Rational prescribing is seizure-specific: narrow-spectrum sodium-channel drugs control focal seizures but can worsen absences and myoclonus, while broad-spectrum agents cover most seizure types. Matching drug to seizure type, knowing each drug's signature toxicities and interactions, and planning around pregnancy are the three habits that define safe AED prescribing.

Propagation of the action potential along a myelinated nerve
Anticonvulsants act on excitable membranes — most by limiting the repetitive high-frequency firing that sodium channels sustain, without blocking the single action potential.

2 Learning Objectives

  • Summarise the five principal mechanisms of anticonvulsant action.
  • Match major drugs to the seizure types they treat — and those they worsen.
  • Detail the pharmacology, dosing and adverse effects of phenytoin, carbamazepine, valproate, ethosuximide, lamotrigine and levetiracetam.
  • Manage toxicity, interactions and therapeutic drug monitoring for classic AEDs.
  • Counsel on pregnancy, contraception and adherence.

3 Principles of Action

A seizure is runaway excitation. Anticonvulsants work by one or more of three broad strategies: (1) limiting repetitive firing at voltage-gated sodium channels; (2) reducing excitatory (glutamatergic) transmission; (3) enhancing inhibitory (GABAergic) transmission. The clinical elegance is frequency dependence: sodium-channel blockers bind preferentially to inactivated channels, so they suppress the rapid trains of firing in a seizure focus while leaving ordinary single action potentials — and therefore normal function — largely untouched.

4 The Five Mechanisms of Action

  1. Sodium-channel blockade — phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, valproate, topiramate, zonisamide.
  2. Calcium-channel blockade — ethosuximide blocks T-type channels in thalamic neurons (absence seizures); gabapentin/pregabalin bind presynaptic α2δ; zonisamide, valproate act on N/L-type.
  3. GABA enhancement — benzodiazepines (allosteric GABAA modulators), phenobarbital (prolongs chloride-channel opening), vigabatrin (irreversibly inhibits GABA transaminase), tiagabine (blocks GABA reuptake), valproate (inhibits GABA transaminase).
  4. Glutamate/NMDA–AMPA antagonism — felbamate, perampanel, topiramate, lamotrigine (reduces glutamate release).
  5. Synaptic vesicle protein binding — levetiracetam binds SV2A, reducing neurotransmitter release; unique, non-CYP metabolism.

5 Drug Monographs: Doses, Indications & Safety

Each monograph below follows the same exam-ready structure: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses; always confirm against the current Uganda Clinical Guidelines before prescribing.

Phenytoin (hydantoin)

Scroll the table sideways on a smaller screen.

Phenytoin — sodium-channel blocker
MechanismBlocks voltage-gated sodium channels (frequency-dependent, use-dependent binding to inactivated channels)
IndicationsFocal seizures, generalised tonic–clonic seizures, status epilepticus (IV/loading)
Adult doseLoading 15–20 mg/kg IV (status, max 50 mg/min) or 1 g oral load; maintenance 300 mg/day (3–5 mg/kg/day) once daily or divided
Paediatric doseMaintenance 4–8 mg/kg/day in 2 divided doses
Adverse effectsNystagmus, diplopia, ataxia, slurred speech, confusion (toxicity); gingival hyperplasia, hirsutism, coarse facies, acne; folate-deficiency megaloblastic anaemia, osteomalacia; SJS/TEN
ContraindicationsSinus bradycardia/AV heart block; porphyria; caution in pregnancy (teratogenic) and liver disease
InteractionsPotent CYP inducer — reduces OCP, warfarin, many antiretroviral levels; metronidazole, cimetidine, fluconazole, valproate raise phenytoin levels; high protein binding (albumin)
Patient advice / monitoringTake with food; never stop abruptly; good oral hygiene (gum hyperplasia); blood levels needed — non-linear kinetics mean small dose increases cause disproportionate level jumps; reliable contraception

Carbamazepine (iminostilbene)

Scroll the table sideways on a smaller screen.

Carbamazepine — sodium-channel blocker
MechanismBlocks voltage-gated sodium channels; reduces glutamate release
IndicationsFirst-line for focal seizures; generalised tonic–clonic seizures; trigeminal neuralgia; bipolar disorder
Adult doseStart 100–200 mg once–twice daily, increase gradually (autoinduction over 2–4 weeks); usual maintenance 400–1,200 mg/day (max 1,600 mg/day) in 2–3 divided doses
Paediatric doseStart 5 mg/kg/day, usual 10–20 mg/kg/day in 2–3 divided doses
Adverse effectsDizziness, diplopia, ataxia, drowsiness, nausea; hyponatraemia/SIADH; SJS/TEN (screen HLA-B*1502 where available); aplastic anaemia, agranulocytosis; hepatotoxicity; teratogenic
ContraindicationsAV heart block; history of bone-marrow depression; MAOI co-therapy; HLA-B*1502-positive patients (avoid); porphyria
InteractionsPotent CYP3A4 inducer — OCP failure, reduced warfarin and antiretroviral effect; erythromycin, clarithromycin, fluconazole, verapamil, diltiazem raise its levels (toxicity); grapefruit juice raises levels; autoinduces its own metabolism
Patient advice / monitoringTake with food, avoid grapefruit; report rash, fever, sore throat, easy bruising, jaundice immediately; baseline + periodic FBC, LFTs, sodium; warn it does not treat absence seizures

Sodium valproate (carboxylic acid)

Scroll the table sideways on a smaller screen.

Sodium valproate — broad-spectrum, multiple mechanisms
MechanismMultiple: sodium-channel blockade, GABA-transaminase inhibition, T-type calcium-channel blockade
IndicationsBroad spectrum — all focal and generalised seizures, absence, myoclonus, juvenile myoclonic epilepsy; bipolar disorder; migraine prophylaxis
Adult doseStart 500 mg/day, usual 1,000–2,000 mg/day (20–30 mg/kg/day); status: IV 20–40 mg/kg
Paediatric dose20–30 mg/kg/day, up to 60 mg/kg/day; avoid in children <2 years on polytherapy
Adverse effectsHepatotoxicity, teratogenicity (neural tube defects, ~10% major malformation rate), weight gain, tremor, hair thinning, GI upset, hyperammonaemic encephalopathy, pancreatitis, PCOS, thrombocytopenia
ContraindicationsSignificant hepatic impairment/urea-cycle disorders; pregnancy unless no alternative; caution in women of childbearing potential
InteractionsInhibitor — raises lamotrigine levels (rash risk) and displaces phenytoin from albumin; carbapenem antibiotics markedly reduce valproate levels; aspirin increases free fraction
Patient advice / monitoringNever in pregnancy — counsel every woman of childbearing potential; folate 5 mg preconception; report jaundice, abdominal pain, unusual bleeding; take with food; monitor LFTs, FBC, weight

Ethosuximide (succinimide)

Scroll the table sideways on a smaller screen.

Ethosuximide — T-type calcium-channel blocker
MechanismBlocks T-type voltage-gated calcium channels in thalamic neurons
IndicationsAbsence seizures (drug of choice for pure absence); ineffective for tonic–clonic seizures
Adult doseStart 250 mg twice daily; usual 750–1,500 mg/day in 2 divided doses
Paediatric doseStart 15 mg/kg/day, usual 20–40 mg/kg/day in 2 divided doses
Adverse effectsGI upset, drowsiness, dizziness, headache, hiccups; rare blood dyscrasias, SLE-like syndrome, psychosis
ContraindicationsHypersensitivity; porphyria (caution); not for mixed seizures with tonic–clonic component
InteractionsValproate raises ethosuximide levels; carbamazepine lowers them
Patient advice / monitoringUnderstand it works only for absence seizures; report rash, fever, sore throat; periodic FBC if long-term; never stop abruptly

Lamotrigine (phenyltriazine)

Scroll the table sideways on a smaller screen.

Lamotrigine — sodium-channel blocker, glutamate release inhibitor
MechanismBlocks voltage-gated sodium channels; reduces glutamate release
IndicationsFocal seizures, generalised seizures, absence (with valproate for mixed), bipolar depression
Adult doseSlow titration is mandatory: 25 mg once daily ×14 days → 50 mg ×14 days → 100–200 mg/day maintenance; if combined with valproate, start 25 mg alternate days (max ~100–200 mg/day); if with carbamazepine/phenytoin, higher doses needed
Paediatric dose>12 years: as adult, slower still; 2–12 years specialist titration from 0.15 mg/kg/day (valproate co-therapy)
Adverse effectsSJS/TEN (risk ↑ with valproate, rapid titration, children); headache, dizziness, nausea, insomnia, tremor; generally cognition-friendly
ContraindicationsHypersensitivity to lamotrigine; caution with valproate co-therapy and previous rash on AEDs
InteractionsValproate doubles its half-life (rash risk); carbamazepine, phenytoin, phenobarbital, rifampicin induce metabolism (lower levels); combined OCP reduces levels ~50%
Patient advice / monitoringReport any rash immediately — stop and seek care; never restart after rash; keep the titration schedule exactly; alert prescribers to OCP use (levels fall)

Levetiracetam (pyrrolidine)

Scroll the table sideways on a smaller screen.

Levetiracetam — synaptic vesicle SV2A ligand
MechanismBinds synaptic vesicle protein SV2A; reduces neurotransmitter release; non-CYP metabolism
IndicationsBroad spectrum — focal seizures (first-line), generalised tonic–clonic, myoclonic seizures, JME, status epilepticus (IV)
Adult doseStart 500 mg twice daily; usual 1,000–3,000 mg/day in 2 divided doses; status: IV 1,000–3,000 mg
Paediatric doseStart 10 mg/kg twice daily, up to 60 mg/kg/day
Adverse effectsSomnolence, dizziness, headache; behavioural changes — irritability, aggression, depression, rarely psychosis; rare rash, neutropenia
ContraindicationsHypersensitivity; caution with significant psychiatric history; reduce dose in renal impairment
InteractionsEssentially none — no CYP450 involvement; probenecid may reduce renal clearance; methotrexate levels may rise
Patient advice / monitoringWatch for mood change — report depression, aggression or suicidal thoughts; safest AED profile in pregnancy; no routine level monitoring needed

Lorazepam (benzodiazepine) — status & acute seizures

Scroll the table sideways on a smaller screen.

Lorazepam — GABAA allosteric modulator
MechanismPotentiates GABAA-mediated chloride influx (allosteric benzodiazepine site)
IndicationsFirst-line for status epilepticus and acute repetitive seizure clusters; myoclonus (short-term)
Adult doseStatus: 4 mg IV (0.1 mg/kg) at 2 mg/min, may repeat once after 10 minutes; IM 4 mg if no IV access; buccal/intranasal midazolam 10 mg is the community alternative
Paediatric dose0.1 mg/kg IV (max 4 mg); buccal midazolam 5 mg (1–9 years) / 10 mg (>10 years)
Adverse effectsSedation, respiratory depression, hypotension, confusion, paradoxical agitation; tolerance and dependence with regular use
ContraindicationsSevere respiratory insufficiency, sleep apnoea, myasthenia gravis, severe hepatic failure
InteractionsAdditive sedation with opioids, alcohol, antihistamines, other CNS depressants
Patient advice / monitoringShort-term/ emergency use only; monitor airway and respiration after IV dose; never mix with alcohol

Phenobarbital (barbiturate)

Scroll the table sideways on a smaller screen.

Phenobarbital — GABAA chloride-channel prolonger
MechanismProlongs GABAA chloride-channel opening; at high doses directly gates the channel
IndicationsAll seizure types (esp. tonic–clonic, focal, neonatal seizures); status epilepticus; cheap mainstay in resource-limited settings
Adult dose60–180 mg/day at night; status/neonatal loading 20 mg/kg IV
Paediatric dose3–6 mg/kg/day; neonates: 20 mg/kg load, then 3–4 mg/kg/day
Adverse effectsSedation, cognitive slowing, behavioural change (hyperactivity in children), nystagmus/ataxia, osteomalacia, dependence; rare SJS
ContraindicationsPorphyria; severe respiratory disease; severe hepatic impairment; caution with depression/suicidality
InteractionsPotent CYP inducer — reduces OCP and warfarin efficacy, lowers many co-prescribed drug levels
Patient advice / monitoringExpect drowsiness at first — no driving until stable; never stop abruptly (rebound seizures); reliable contraception needed; serum levels available (toxicity >40 mg/L)

6 Seizure-Type Selection

Scroll the table sideways on a smaller screen.

Seizure typeFirst-line optionsAvoid / caution
Focal-onsetCarbamazepine, lamotrigine, levetiracetam, valproate—
Generalised tonic–clonicValproate, lamotrigine, levetiracetam, phenytoin, carbamazepine—
AbsenceEthosuximide (pure absence), valproate, lamotrigineCarbamazepine, phenytoin — worsen absences
Myoclonic / juvenile myoclonic epilepsyValproate, levetiracetam, lamotrigine (caution — can worsen myoclonus)Carbamazepine, phenytoin — exacerbate
Infantile spasmsHormonal therapy (ACTH/prednisolone), vigabatrin (tuberous sclerosis)—
Status epilepticusLorazepam → phenytoin/fosphenytoin or valproate or levetiracetam → anaesthesia—

7 Adverse Effects & Toxicity

  • Phenytoin toxicity — nystagmus, diplopia, ataxia, slurred speech, confusion; chronic: gingival hyperplasia, hirsutism, neuropathy, osteomalacia. Non-linear kinetics make levels essential after dose changes.
  • Rash syndromes — carbamazepine, phenytoin, lamotrigine (and phenobarbital) share an aromatic-AED risk of SJS/TEN; HLA-B*1502 (carbamazepine) and HLA-A*3101 screening where available; slow lamotrigine titration is mandatory.
  • Valproate — hepatotoxicity (young children, polytherapy), teratogenicity, hyperammonaemia, pancreatitis; monitor LFTs, ammonia if encephalopathic.
  • Haematologic — carbamazepine (aplastic anaemia, agranulocytosis), felbamate (aplastic anaemia/hepatic failure — reserved), phenytoin (megaloblastic anaemia from folate depletion).
  • Cognitive/psychiatric — barbiturates and topiramate slow cognition (word-finding); levetiracetam can cause irritability and depression.

8 Interactions & Monitoring

  • Enzyme inducers — phenytoin, carbamazepine, phenobarbital induce CYP3A4: reduce oral contraceptive reliability (advise alternative methods), lower warfarin, many antiretrovirals and other AED levels.
  • Valproate inhibits — raises lamotrigine (rash risk) and phenytoin levels; competes for protein binding.
  • Therapeutic drug monitoring — most valuable for phenytoin, carbamazepine, phenobarbital and valproate (check trough levels; levetiracetam and lamotrigine rarely need routine levels). Monitoring helps non-adherence, toxicity, pregnancy, suspected interactions and breakthrough seizures.
  • Adherence — single daily-dose agents where possible; missed doses are the commonest cause of breakthrough seizures; never stop abruptly (rebound seizures/status risk).

9 Pregnancy & Special Populations

  • Pregnancy — all AEDs carry some teratogenic risk; valproate is the worst (neural tube defects, cognitive impairment, autistic spectrum) and should be avoided in women of childbearing potential unless alternatives fail. Folate 5 mg daily preconception reduces neural-tube risk. Choose the lowest effective dose of the safest drug (lamotrigine, levetiracetam have the best profiles), plan pregnancy with neurology, and monitor levels in pregnancy (clearance rises; dose increases often needed — then reduce postpartum).
  • Breastfeeding — generally allowed with lamotrigine, levetiracetam, valproate (low transfer); avoid sedating barbiturates if possible.
  • Children — avoid valproate under 2 years (hepatotoxicity); ethosuximide/valproate for absence; many classic drugs need weight-based dosing.
  • Elderly — low starting doses, slow titration; watch hyponatraemia (carbamazepine/oxcarbazepine), falls from ataxia, and interactions with polypharmacy.
  • HIV/TB co-therapy — enzyme inducers lower antiretroviral and anti-tuberculous drug levels (and rifampicin lowers AED levels) — a daily reality in Ugandan practice; involve specialists.

10 Viva & Exam Points

  • Mechanisms — Na⁺ blockade (phenytoin, carbamazepine, lamotrigine), T-type Ca²⁺ blockade (ethosuximide), GABA enhancement (benzos, barbiturates, vigabatrin), glutamate blockade, SV2A binding (levetiracetam).
  • Absence — ethosuximide; myoclonic — valproate; narrow-spectrum drugs worsen both.
  • Phenytoin — non-linear kinetics, gingival hyperplasia, CYP inducer, nystagmus-ataxia toxicity.
  • Carbamazepine — autoinduction, HLA-B*1502/SJS, hyponatraemia, enzyme inducer.
  • Valproate — broad spectrum, hepatotoxic, teratogenic, inhibitor.
  • Lamotrigine — slow titration, SJS risk; levetiracetam — behavioural effects, no interactions.
  • Status — lorazepam IV first, then levetiracetam/valproate/fosphenytoin.

11 References

For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top